BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liebe R, Esposito I, Bock HH, Vom Dahl S, Stindt J, Baumann U, Luedde T, Keitel V. Diagnosis and management of secondary causes of steatohepatitis. J Hepatol 2021;74:1455-71. [PMID: 33577920 DOI: 10.1016/j.jhep.2021.01.045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Barrios V, López-Villar E, Frago LM, Canelles S, Díaz-González F, Burgos-Ramos E, Frühbeck G, Chowen JA, Argente J. Cerebral Insulin Bolus Revokes the Changes in Hepatic Lipid Metabolism Induced by Chronic Central Leptin Infusion. Cells 2021;10:581. [PMID: 33800837 DOI: 10.3390/cells10030581] [Reference Citation Analysis]
2 Alalwani J, Eljazzar S, Basil M, Tayyem R. The impact of health status, diet and lifestyle on non‐alcoholic fatty liver disease: Narrative review. Clinical Obesity. [DOI: 10.1111/cob.12525] [Reference Citation Analysis]
3 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
4 Von-hafe M, Borges-canha M, Vale C, Leite AR, Sérgio Neves J, Carvalho D, Leite-moreira A. Nonalcoholic Fatty Liver Disease and Endocrine Axes—A Scoping Review. Metabolites 2022;12:298. [DOI: 10.3390/metabo12040298] [Reference Citation Analysis]
5 Kotha S, Berry P. Multiple investigations for a very common disorder: Finding the right balance in NAFLD. J Hepatol 2021;75:1501-2. [PMID: 34228993 DOI: 10.1016/j.jhep.2021.06.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zhang Y, Lin S, Peng J, Liang X, Yang Q, Bai X, Li Y, Li J, Dong W, Wang Y, Huang Y, Pei Y, Guo J, Zhao W, Zhang Z, Liu M, Zhu AJ. Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. Mol Cell 2022:S1097-2765(22)00086-7. [PMID: 35245436 DOI: 10.1016/j.molcel.2022.01.021] [Reference Citation Analysis]
7 Michel M, Labenz C, Anders M, Wahl A, Girolstein L, Kaps L, Kremer WM, Huber Y, Galle PR, Sprinzl M, Schattenberg JM. Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV. Hepatol Commun 2022. [PMID: 35411570 DOI: 10.1002/hep4.1958] [Reference Citation Analysis]
8 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
9 Luedde T, Baumann U, Keitel V. Reply to: "Multiple investigations for a very common disorder: Finding the right balance in NAFLD". J Hepatol 2021;75:1502-3. [PMID: 34520784 DOI: 10.1016/j.jhep.2021.08.032] [Reference Citation Analysis]
10 Lonardo A. Separating the apples from the oranges: from NAFLD heterogeneity to personalized medicine. Exploration of Medicine. [DOI: 10.37349/emed.2021.00061] [Reference Citation Analysis]
11 Lonardo A. Metabolomic signature: one step forward in the process of obtaining NAFLD patients' metabolic identity card. Am J Clin Nutr 2022;115:603-5. [PMID: 35134121 DOI: 10.1093/ajcn/nqab399] [Reference Citation Analysis]
12 Chen Z, Chen L, Sun B, Liu D, He Y, Qi L, Li G, Han Z, Zhan L, Zhang S, Zhu K, Luo Y, Chen L, Zhang N, Guo H. LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway. Mol Metab 2021;51:101230. [PMID: 33823318 DOI: 10.1016/j.molmet.2021.101230] [Reference Citation Analysis]
13 Querter I, de Bruyne R, Geerts A, Lefere S. Reply. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00975-7. [PMID: 34536580 DOI: 10.1016/j.cgh.2021.09.011] [Reference Citation Analysis]